Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma in the setting of clinical node positive disease: analysis of the ROBUUST registry.
Recommended Citation
Meagher MF, Wu Z, Franco A, Wang L, Margulis V, Bhanvadia R, Abdollah F, Finati M, Antonelli A, Ditonno F, Singla N, Brönimann S, Simone G, Proietti F, Tuderti G, Puri D, Birouty N, Musso G, Dabbas M, Rais-Bahrami S, Moon SC, Ferro M, Tozzi M, Porpiglia F, Checcucci E, Correa AF, Helstrom E, Gonzalgo ML, Mendiola DF, Perdonà S, Tufano A, Eilender BM, Mehrazin R, Yong C, Sundaram CP, Ghoreifi A, Djaladat H, Autorino R, and Derweesh IH. Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma in the setting of clinical node positive disease: analysis of the ROBUUST registry. World J Urol 2025;44(1):1.
Document Type
Article
Publication Date
11-26-2025
Publication Title
World journal of urology
Keywords
Adjuvant; Chemotherapy; Neoadjuvant; Nephroureterectomy; Survival analysis; Upper tract urothelial carcinoma
PubMed ID
41296050
Volume
44
Issue
1
First Page
1
Last Page
1
